Journal of Neuroscience study examines medicinal properties of cannabis
OHSU research suggests an avenue for developing treatments for chronic pain that harness the medicinal properties of cannabis while minimizing the threat of addiction.
The study, conducted in a rodent model, provides additional rationale for the development of therapeutics using cannabinoid receptors to treat chronic pain, which afflicts about 30 percent of the U.S. population. OHSU investigators studied the function of two forms of cell membrane receptors that bind cannabinoids that occur naturally within the body, called endocannabinoids.
“It may be an avenue where we can get better pain medications that are not addictive,” said senior author Susan Ingram, Ph.D., an associate professor of neurosurgery in the OHSU School of Medicine.
Ingram and colleagues report the treatment of chronic pain has challenged the medical system, with medications that are ineffective or create serious side effects: “However, emerging data indicate that drugs that target the endocannabinoid system might produce analgesia with fewer side effects compared with opioids.”
The body’s endocannabinoid system comprises receptors, endocannabinoid molecules and enzymes that make and degrade the endocannabinoids located in the brain and throughout the central and peripheral nervous system. The research team focused on two cannabinoid receptors, known as CB1 and CB2, in the rostral ventromedial medulla – a group of neurons located in the brainstem known to modulate pain. The study is the first to examine CB1 and CB2 receptor function at the membrane level in late adolescent and adult neurons.
The researchers observed that chronic inflammatory pain increased activity of CB2 receptors and decreased CB1 activity. Cannabis activates both CB1 and CB2 receptors equally. The study suggests that selective activation of CB2 receptors contributes to the medicinal benefit of cannabis while minimizing the propensity of the other cannabinoid receptor, CB1, to induce tolerance and withdrawal. Ingram said the next phase of the research will further explore this area of brain circuitry, which ultimately could lead to the development of a new class of pain medications.
Receive an email update when we add a new PAIN article.
The Latest on: Non-addictive pain relief
via Google News
The Latest on: Non-addictive pain relief
- Best CBD Oil for Sleep and Insomniaon March 17, 2020 at 1:45 pm
Sleep disturbance and insomnia relief. We specifically wanted to know how effective each brand was at alleviating ... and ability to not cause internal harm as some of the main reasons why they swear ...
- Opioids Don't Seem To Provide Better Pain Relief For Tooth Extractionson March 13, 2020 at 3:33 pm
The rest were given non-addictive painkillers such as parcetamol or ibuprofen ... “I think it's an extremely liberating finding for dentists who can worry more about the most effective pain relief ...
- More employers opening door to acupuncture as demand for drug-free care growson March 13, 2020 at 8:12 am
Acupuncture is a treatment to relieve pain rooted in Chinese medical tradition that involves inserting needles at different strategic points on the body.
- Medical marijuana bill passes Senateon March 12, 2020 at 11:20 pm
Tim Melson, R-Florence, said he believes medical marijuana can bring pain relief to many Alabamians. He's worked on the legislation for ... based on the research that I've seen, and being ...
- Medical marijuana bill passes Alabama Senateon March 12, 2020 at 6:25 pm
The Alabama Senate on Thursday passed legislation to allow and regulate medical marijuana after five hours of debate.
- Looking to the future with Dr. Francis Collinson March 12, 2020 at 8:54 am
The NIH’s Helping to End Addiction Long-term (HEAL) initiative is an “all-hands-on-deck” effort, he said, involving almost every NIH institute and center, with the goal of uncovering new targets for ...
- P2X7 Receptor Antagonists Market Poised to Achieve Significant Growth in the Years to Comeon March 12, 2020 at 12:00 am
Global P2X7 Receptor Antagonist Market - Insights The P2X7 receptor is an ATP-gated, non-selective cation channel, which results in several downstream events such as including the release of ...
- Antibe Therapeutics Announces Research Publication Demonstrating Markedly Enhanced Pain Relief and Increased Safety of Second Pipeline Drugon March 11, 2020 at 3:12 am
ANTIBE THERAPEUTICS ANNOUNCES RESEARCH PUBLICATION DEMONSTRATING MARKEDLY ENHANCED PAIN RELIEF AND INCREASED SAFETY OF SECOND PIPELINE DRUG ...
- American Council on Science and Health hails Antibe's ATB-346 as potential breakthrough in pain medon March 10, 2020 at 12:03 pm
non-addictive drugs for pain management. The Toronto-based biotech is at the forefront of shaking up a $11 billion industry with a revolutionary new product that provides the relief of opioids without ...
via Bing News